Sciex (Framingham, Massachusetts, USA) has announced a co‑marketing agreement with Pressure BioSciences, Inc. (South Easton, MA, USA), which aims to address the challenges arising in complex sample preparation.
Sciex (Framingham, Massachusetts, USA) has announced a coâmarketing agreement with Pressure BioSciences, Inc. (South Easton, MA, USA), which aims to address the challenges arising in complex sample preparation. This joint venture will enable Sciex to market a complete service to increase the depth, breadth, and reproducibility of protein extraction, digestion, and quantitation in all tissue types, including challenging samples like tumours.
“Advancing precision medicine through the ability to reproducibly quantitate thousands of proteins in large clinical sample cohorts is of the utmost importance to both academic and clinical research labs,” said Mark Cafazzo, Director of Academic and Clinical Research Business at Sciex.
Through combining technological knowledge Pressure BioSciences, Inc. and Sciex hope to help “scientists address the sample preparation challenges they face every day, especially when working with difficult tissue samples.”
Mr. Cafazzo continued: “The net result is more comprehensive protein quantitation from complex samples, increased productivity, and higher quality results. This is an exciting step forward for the field of proteomics, one that offers the potential to make a great and lasting impact on the quality of human life.”
Richard T. Schumacher, President and CEO of Pressure BioSciences, Inc., commented: “By combining [our] methods with Sciex’s expertise and successful history in mass spectrometry system solutions, clinical researchers will be equipped to make major leaps forward in proteomic analysis, over the current limitations of traditional methods.”
Sciex and Pressure BioSciences, Inc. hope this deal will significantly expand the footprint of MS-based quantitation workflows in clinical research settings worldwide.
For more information please visit www.sciex.com and www.pressurebiosciences.com
Exploring Metabolite Alteration from Age-Related Macular Degeneration with UHPLC-MS/MS
February 19th 2025Exploring the alterations in metabolites of wet age-related macular degeneration (wAMD), metabolomic analysis was performed on the aqueous humor of 30 patients with wAMD receiving anti-vascular endothelial growth factor (anti-VEGF) treatments and 20 controls, via ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS).
The Next Frontier for Mass Spectrometry: Maximizing Ion Utilization
January 20th 2025In this podcast, Daniel DeBord, CTO of MOBILion Systems, describes a new high resolution mass spectrometry approach that promises to increase speed and sensitivity in omics applications. MOBILion recently introduced the PAMAF mode of operation, which stands for parallel accumulation with mobility aligned fragmentation. It substantially increases the fraction of ions used for mass spectrometry analysis by replacing the functionality of the quadrupole with high resolution ion mobility. Listen to learn more about this exciting new development.